Related Experiment Video
Updated: May 29, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Preoperative Weight Loss Intervention With Glucagon-Like Peptides 1 Receptor Agonists Is Associated With Lower
George Bcharah1, Austin E Wininger1, Zaid Elsabbagh2
1Department of Orthopaedic Surgery, Mayo Clinic Hospital, Phoenix, AZ, USA.
Background:
Obesity is a risk factor for adverse outcomes following total knee arthroplasty (TKA). Bariatric surgery (BS) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are weight-loss strategies commonly encountered in TKA patients. This study aimed to compare short- and long-term complications among obese patients treated with either BS or GLP-1 RAs prior to TKA.
Methods:
The database was queried to identify patients with obesity (body mass index [BMI] ≥35 kg/m2) undergoing primary TKA. Patients were stratified based on interventions within 1 year prior to surgery: BS, GLP-1 RA, and no weight-loss intervention. Propensity score matching was performed to balance baseline characteristics. Subgroup analyses were conducted for BMI 35-40 kg/m2 and >40 kg/m2. Primary outcomes included periprosthetic joint infection (PJI), aseptic loosening, periprosthetic fracture, and revision surgery at 90 days, 2 years, and 5 years.
Results:
In the matched BMI ≥35 kg/m2 cohort (n = 3635 per group), patients with prior BS had significantly higher odds of all surgical complications, including PJI (odds ratio [OR]: 1.70) and all-cause revision (OR: 1.69) compared to the GLP-1 RA cohort. Compared to the no-intervention cohort, BS was associated with increased risks of PJI (OR: 1.33) and periprosthetic fracture (OR: 2.01). Conversely, the GLP-1 RA cohort showed significantly lower risks of surgical complications compared to the no-intervention cohort across most time points and BMI subgroups.
Conclusions:
Preoperative GLP-1 RA use is associated with lower complication rates than BS and demonstrates a protective safety profile compared with no weight-loss intervention, underscoring their potential role in preoperative obesity patients undergoing TKA.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
